Agenus (AGEN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agenus (AGEN)

AGEN 3.750

-5.4%

11:52 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (9)	2/19/2004 5:15:50 PM
From: Area51	of 146

Confernce call: biz.yahoo.com 2004 Net cash burn estimated as 70 - 75 million. Therefore they have enough cash to fund through end of 2005. 2004 major milestones: (i) Prepare for product launch of Ocnophage pending completion of PIII Ocnophage trials (ii) Final PIII RCC data available by end of year (iii)Phase III Ocnophage melanoma trials: Complete enrollment by EOY, results by midyear 2005 (iv)complete enrollment of AG858 Gleevac trial by midyear (40 patient trial, 20 currently enrolled; goal is to get some data to justify larger trial) (v) initiate clinical trials of AG707 (genital herpes) (vi) Continue discussions with oncology pharma regarding partnership or collaboration (Garo said they had discussions with 7 of 13 top oncology pharma. They are prepared to go it alone in US if necessary, but want to partner the worldwide rights as a minimum. I thought it was a good call. My sense was that long term buyers could buy here around $10 and expect an excellent return on investment by 2005 (presuming the RCC Ocnophage results are statistically significant). What do others think regarding AGEN prospects?? Best Regards, Area51

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next